HOUSTON, TX – DM Clinical Research is celebrating its 20th anniversary, marking two decades of expanding access to clinical trials and helping accelerate the development of innovative therapies for patients across the United States. Founded in 2006 with a vision to make clinical research more accessible and patient-centered, DM Clinical has grown into one of the nation's leading integrated clinical research networks, according to a company announcement.
Over the past 20 years, the organization expanded its national footprint, therapeutic expertise, and research capabilities while remaining focused on accelerating access to innovative therapies. Today, DM Clinical Research operates a growing network of more than 35 research sites, providing access to a patient population of 1.97 million individuals across 32 therapeutic areas. The company has enrolled more than 35,000 patients in clinical trials over the past two decades, helping advance the development of safe, life-changing therapies for patients and communities around the world.
"Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey," said Mohammad Millwala, Founder and CEO of DM Clinical Research. "We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference. I'm incredibly proud of what we've built together, and I'm even more excited about what we can accomplish in the next 20 years."
DM Clinical Research partners with leading pharmaceutical, biotechnology, healthcare organizations, and contract research organizations to conduct high-quality clinical trials while delivering strong enrollment performance, diverse patient access, and operational excellence. As part of its mission to expand access to clinical research, DM Clinical Research continues to grow its presence in underserved communities, helping ensure more patients have the opportunity to participate in life-changing clinical trials. Through its integrated operating model, DM Clinical combines local physician relationships and patient access with centralized infrastructure designed to deliver quality, speed, and consistent execution for sponsors and CRO partners.
This commitment to excellence and patient impact has been recognized through industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, CEO Mohammad Millwala was also honored with the SCRS Christine K. Pierre Site Impact Award, recognizing his leadership and contributions to advancing clinical research.
The company's 20th anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork, innovation, and dedication that have fueled its growth over the past two decades. Guided by its core values—Think Forward, Find a Way, Create Impact, Own It, and Win Together—DM Clinical continues to invest in its people, expand access to research, and help bring new therapies to patients faster.
"As we celebrate this milestone, we remain focused on what's next," added Millwala. "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives."
As DM Clinical enters its third decade, the company plans continued expansion into new communities, broader therapeutic expertise, and increased investment in innovative technologies that improve patient access to clinical research. The implications of this milestone are significant for the clinical research industry, as DM Clinical's growth reflects a broader trend toward patient-centric and accessible trial models. The company's focus on underserved communities and diverse patient populations addresses a critical need for inclusivity in clinical trials, which can lead to more effective and generalizable medical treatments. Moreover, its integrated network and technology investments aim to streamline trial processes, potentially reducing drug development timelines and costs. For patients, this means more opportunities to participate in cutting-edge research close to home. For sponsors and CROs, DM Clinical's proven track record offers a reliable partner for high-quality, diverse enrollment. As the company expands, it is poised to play an even larger role in bringing innovative therapies to market, benefiting patients worldwide.
